Biotech Values

[DewDiligence]

VLON IPOs 2.59M* shares @$8.00:

https://www.globenewswire.com/news-release/2021/02/10/2172754/0/en/Vallon-Pharmaceuticals-Announces-Pricing-of-Initial-Public-Offering.html

Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.

This is one of the smallest biotech IPOs in recent memory.

*Assuming exercise of underwriter’s option.